Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study assessed ritlecitinib's effects on sustained hair regrowth in patients with alopecia areata who showed improvement at 24 weeks, confirming ongoing benefits through 48 weeks for scalp, eyebrow, and eyelash hair regrowth in this post hoc analysis.

In this study, overweight women with polycystic ovarian syndrome who took evening primrose oil for 10 weeks experienced significant reductions in BMI, LDL, and total cholesterol levels, alongside hormonal changes such as decreased LH, FSH, and testosterone levels, and increased estrogen.

In this study, using a shampoo with Morus alba root extract over 12 weeks increased hair density and shaft thickness in patients with mild to moderate non-scarring alopecia, with both investigators and participants noting visible improvements and moderate satisfaction.

This study found that in participants with notalgia paresthetica, 8 weeks of treatment with difelikefalin significantly improved itch intensity and increased the rate of strict complete response compared to placebo, starting as early as week 3.

This study reports that a patient with rare linear lichen planopilaris experienced complete hair regrowth after 12 weeks of treatment with the antibody ixekizumab, suggesting it as a potential targeted therapy.

This case report describes successful treatment of mange in a rabbit using topical selamectin over two weeks.

This study found that applying 2% topical minoxidil resulted in a greater nail growth rate compared to 5% minoxidil and placebo over eight weeks, with no observed side effects, suggesting 2% is an effective concentration for accelerating nail growth.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

This study found that there was no significant difference in hair regrowth between clobetasol and bimatoprost for scalp alopecia areata over 12 weeks, but bimatoprost had fewer side effects and prompted earlier, more pigmented hair regrowth.

This case report describes a 3-month-old infant with acquired acrodermatitis enteropathica who was successfully treated with zinc supplementation over 3 weeks.

This case report describes a 7-year-old boy who developed telogen effluvium resulting in unilateral ciliary madarosis nine weeks after COVID-19 infection, with no other causes identified.

This study found that liquid nitrogen cryotherapy significantly improved alopecia areata in 27.4% of treated patients after six weeks, with no association between treatment efficacy and factors like age or gender.

This study reported that topical azelaic acid cream 20% demonstrated statistically significant efficacy in treating localized alopecia areata of the scalp over 12 weeks, comparable to topical clobetasol ointment 0.05%, suggesting it as a potential therapeutic option.

This study found that a powder made from papaya seeds and celery leaves remained stable for 3 weeks when stored at room or cold temperatures, suggesting potential for hair health applications.

This study found that both oral minoxidil and topical 5% minoxidil were effective and safe for treating female pattern hair loss over 24 weeks, with oral administration not being inferior to topical treatment.

In this study, daily administration of 100mg DHEA for 16 weeks in women with adequate ovarian reserve did not modify metabolic or reproductive variables, apart from increased antral follicular count and anti-Müllerian hormone levels.

This study found that adalimumab treatment led to regression of lesions in two patients with hidradenitis suppurativa after 16 weeks of therapy.

In this randomized clinical trial, the use of Cellcurin serum for 12 weeks was associated with a significant increase in hair density and terminal hair thickness in individuals with androgenetic alopecia.

This study reported that GA 0.1% spray led to only slight improvement in treating anogenital warts among HIV-positive patients over twelve weeks.

In this study, oral minoxidil at a dose of 1.25 mg/day for 24 weeks was examined as a sole treatment for androgenetic alopecia in 32 patients, including those who had not responded to prior topical minoxidil or oral finasteride therapies.

This study reported that using a herbal hair oil containing Cereus grandiflorus (cactus) Flower extract over 12 weeks was effective in significantly reducing hair fall and aiding new hair growth among alopecia patients.

This study observed that 5% minoxidil milky lotion increased hair density more than the standard solution at 8 weeks in males with androgenetic alopecia, but their efficacy was similar at later visits.

This case study described a young man who experienced acute liver failure requiring a transplant after taking Roaccutane for six weeks for severe acne.

This study observed that a herbal product containing Rosa multiflora roots significantly increased hair density and thickness in patients over 16 weeks, suggesting potential for hair growth promotion and hair loss prevention.

Cortisone may help hair regrow by altering the local environment, with regrowth starting 3-4 weeks after treatment, but its use is not widely recommended.

In this study, the researchers found that the topical generic 5% new minoxidil foam is as effective and safe as the 5% Rogaine® foam in increasing hair density and diameter in men with androgenetic alopecia over 24 weeks.

In this study, combining photobiomodulation therapy and pulsed electromagnetic field therapy over 24 weeks significantly increased hair density in androgenetic alopecia patients compared to a sham device control, with minimal side effects reported.

This placebo-controlled study found that topical procyanidin B2 significantly increased total and anagen hair counts in men with androgenetic alopecia over 16 weeks compared to placebo, suggesting it as an effective and safe treatment option.

This study found that low-level laser therapy significantly increased hair density and thickness in patients with androgenic alopecia over 8 and 16 weeks.